Our scientific researches involve antiretroviral therapy for HIV
infection, its metabolic adverse effects (dyslipidaemia and
diabetes), and risk factors for cardiovascular diseases in
HIV-infected subjects receiving antiretroviral treatment. Our
studies concerne also therapeutic drug monitoring (TDM) of
antiretroviral agents and lipid-lowering drugs (statins) in
HIV-infected individuals, in the context of potential
pharmacokinetic interactions between these compounds, and the risk
of hepatotoxicity in HIV-HCV-coinfected subjects. Finally, we are
assessing prevalence of HBV infection in HIV-positive patients and
the correlation between HBV infection and progression to end stage
liver disease.
